NASDAQ:TARS - Nasdaq - US87650L1035 - Common Stock - Currency: USD
Overall TARS gets a fundamental rating of 4 out of 10. We evaluated TARS against 194 industry peers in the Pharmaceuticals industry. TARS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TARS shows excellent growth, but is valued quite expensive already.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -20.96% | ||
ROE | -30.64% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 92.99% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Altman-Z | 5.8 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 5.57 | ||
Quick Ratio | 5.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 21.08 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:TARS (8/1/2025, 3:10:05 PM)
40.51
+1.69 (+4.35%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | 21.08 | ||
P/S | 7.28 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.97 | ||
P/tB | 5.09 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -20.96% | ||
ROE | -30.64% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 92.99% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 493.5% | ||
Cap/Sales | 2.99% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 5.57 | ||
Quick Ratio | 5.54 | ||
Altman-Z | 5.8 |